Skip to main content
Erschienen in: Journal of Gastroenterology 11/2019

28.03.2019 | Original Article—Alimentary Tract

Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer

verfasst von: Shuwei Li, Kaili Xu, Dongying Gu, Lei He, Lisheng Xie, Zhengxin Chen, Zhimin Fan, Lingjun Zhu, Mulong Du, Haiyan Chu, Zhengdong Zhang, Yuan Wu, Min Ni, Meilin Wang

Erschienen in: Journal of Gastroenterology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Oxaliplatin (L-OHP) is a commonly used first-line chemotherapy for colorectal cancer. Genetic variants in nucleotide excision repair (NER) pathway genes may alter genomic integrity and the efficacy of oxaliplatin-based chemotherapy in colorectal cancer.

Methods

We investigated the association between genetic variants in 19 NER pathway genes and the disease control rate (DCR) and progression-free survival (PFS) among 166 colorectal cancer patients who received oxaliplatin-based chemotherapy. Expression quantitative trait loci (eQTL) analysis was performed using the Genotype-Tissue Expression (GTEx) portal. Gene harboring significant SNP was overexpressed or knocked down to demonstrate the effect on cell phenotypes with or without oxaliplatin treatment.

Results

We found that rs5030740, located in the 3′-untranslated region (3′-UTR) of RPA1, was associated with DCR [OR = 2.99 (1.33–5.69), P = 4.00 × 10−3] and PFS [HR = 1.86 (1.30–2.68), P = 7.39 × 10−4]. The C allele was significantly associated with higher RPA1 mRNA expression levels according to eQTL analysis (P = 0.010 for sigmoid colon and P = 0.004 for transverse colon). The C allele of rs5030740 disrupted let-7e-5p binding to enhance RPA1 expression. Functionally, RPA1 knockdown inhibited cell proliferation and promoted cell apoptosis, whereas RPA1 overexpression promoted proliferation and suppressed apoptosis. Furthermore, low RPA1 expression increased sensitivity to oxaliplatin in colon cancer cells and inhibited proliferation after oxaliplatin treatment.

Conclusions

Our findings demonstrate an association between rs5030740 and the DCR and PFS of colorectal cancer patients. RPA1 functions as a putative oncogene in tumorigenesis by reducing sensitivity to oxaliplatin and could serve as a potential prognostic biomarker in colorectal cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics. CA Cancer J Clin. 2017;67:177–93.CrossRef Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics. CA Cancer J Clin. 2017;67:177–93.CrossRef
2.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRef
3.
Zurück zum Zitat Seal BS, Sullivan SD, Ramsey SD, et al. Systemic therapy for colorectal cancer: patterns of chemotherapy and biologic therapy use in nationally representative US claims database. BioDrugs. 2014;28:229–36.CrossRef Seal BS, Sullivan SD, Ramsey SD, et al. Systemic therapy for colorectal cancer: patterns of chemotherapy and biologic therapy use in nationally representative US claims database. BioDrugs. 2014;28:229–36.CrossRef
4.
Zurück zum Zitat Edwards BK, Noone AM, Mariotto AB, et al. Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290–314.CrossRef Edwards BK, Noone AM, Mariotto AB, et al. Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290–314.CrossRef
5.
Zurück zum Zitat Faivre S, Chan D, Salinas R, et al. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol. 2003;66:225–37.CrossRef Faivre S, Chan D, Salinas R, et al. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol. 2003;66:225–37.CrossRef
6.
Zurück zum Zitat Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.CrossRef Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.CrossRef
7.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.CrossRef Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.CrossRef
8.
Zurück zum Zitat Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705.CrossRef Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705.CrossRef
9.
Zurück zum Zitat Cecchin E, D’Andrea M, Lonardi S, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J. 2013;13:403–9.CrossRef Cecchin E, D’Andrea M, Lonardi S, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J. 2013;13:403–9.CrossRef
10.
Zurück zum Zitat Martinez-Balibrea E, Martinez-Cardus A, Gines A, et al. Tumor-related molecular mechanisms of oxaliplatin resistance. Mol Cancer Ther. 2015;14:1767–76.CrossRef Martinez-Balibrea E, Martinez-Cardus A, Gines A, et al. Tumor-related molecular mechanisms of oxaliplatin resistance. Mol Cancer Ther. 2015;14:1767–76.CrossRef
11.
Zurück zum Zitat Bernstein C, Bernstein H, Payne CM, et al. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res. 2002;511:145–78.CrossRef Bernstein C, Bernstein H, Payne CM, et al. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res. 2002;511:145–78.CrossRef
12.
Zurück zum Zitat de Laat WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev. 1999;13:768–85.CrossRef de Laat WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev. 1999;13:768–85.CrossRef
13.
Zurück zum Zitat Li Z, Qing Y, Guan W, et al. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Cancer Chemother Pharmacol. 2014;74:777–86.CrossRef Li Z, Qing Y, Guan W, et al. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Cancer Chemother Pharmacol. 2014;74:777–86.CrossRef
14.
Zurück zum Zitat McNeil EM, Melton DW. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res. 2012;40:9990–10004.CrossRef McNeil EM, Melton DW. DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic Acids Res. 2012;40:9990–10004.CrossRef
15.
Zurück zum Zitat Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis. 2000;21:551–5.CrossRef Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis. 2000;21:551–5.CrossRef
16.
Zurück zum Zitat Duell EJ, Wiencke JK, Cheng TJ, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis. 2000;21:965–71.CrossRef Duell EJ, Wiencke JK, Cheng TJ, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis. 2000;21:965–71.CrossRef
17.
Zurück zum Zitat Huang MY, Huang ML, Chen MJ, et al. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genom. 2011;21:18–25.CrossRef Huang MY, Huang ML, Chen MJ, et al. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genom. 2011;21:18–25.CrossRef
18.
Zurück zum Zitat McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010;28:3227–33.CrossRef McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010;28:3227–33.CrossRef
19.
Zurück zum Zitat Wang M, Gu D, Du M, et al. Common genetic variation in ETV6 is associated with colorectal cancer susceptibility. Nat Commun. 2016;7:11478.CrossRef Wang M, Gu D, Du M, et al. Common genetic variation in ETV6 is associated with colorectal cancer susceptibility. Nat Commun. 2016;7:11478.CrossRef
20.
Zurück zum Zitat Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279–84.CrossRef Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279–84.CrossRef
21.
Zurück zum Zitat Moreno V, Gemignani F, Landi S, et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res. 2006;12:2101–8.CrossRef Moreno V, Gemignani F, Landi S, et al. Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res. 2006;12:2101–8.CrossRef
22.
Zurück zum Zitat Kap EJ, Seibold P, Richter S, et al. Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer. Pharmacogenomics J. 2015;15:505–12.CrossRef Kap EJ, Seibold P, Richter S, et al. Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer. Pharmacogenomics J. 2015;15:505–12.CrossRef
23.
Zurück zum Zitat Wang F, Zhang SD, Xu HM, et al. XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer. Oncotarget. 2016;7:11724–32.PubMedPubMedCentral Wang F, Zhang SD, Xu HM, et al. XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer. Oncotarget. 2016;7:11724–32.PubMedPubMedCentral
24.
Zurück zum Zitat Nouspikel T. DNA repair in mammalian cells: nucleotide excision repair: variations on versatility. Cell Mol Life Sci. 2009;66:994–1009.CrossRef Nouspikel T. DNA repair in mammalian cells: nucleotide excision repair: variations on versatility. Cell Mol Life Sci. 2009;66:994–1009.CrossRef
25.
Zurück zum Zitat Kubiczkova L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014;99:511–8.CrossRef Kubiczkova L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica. 2014;99:511–8.CrossRef
26.
Zurück zum Zitat Dahai Y, Sanyuan S, Hong L, et al. A relationship between replication protein A and occurrence and prognosis of esophageal carcinoma. Cell Biochem Biophys. 2013;67:175–80.CrossRef Dahai Y, Sanyuan S, Hong L, et al. A relationship between replication protein A and occurrence and prognosis of esophageal carcinoma. Cell Biochem Biophys. 2013;67:175–80.CrossRef
27.
Zurück zum Zitat Hoxha M, Fabris S, Agnelli L, et al. Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2014;53:612–21.CrossRef Hoxha M, Fabris S, Agnelli L, et al. Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia. Genes Chromosomes Cancer. 2014;53:612–21.CrossRef
28.
Zurück zum Zitat Levidou G, Gakiopoulou H, Kavantzas N, et al. Prognostic significance of replication protein A (RPA) expression levels in bladder urothelial carcinoma. BJU Int. 2011;108:E59–65.CrossRef Levidou G, Gakiopoulou H, Kavantzas N, et al. Prognostic significance of replication protein A (RPA) expression levels in bladder urothelial carcinoma. BJU Int. 2011;108:E59–65.CrossRef
29.
Zurück zum Zitat Aboussekhra A, Biggerstaff M, Shivji MK, et al. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell. 1995;80:859–68.CrossRef Aboussekhra A, Biggerstaff M, Shivji MK, et al. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell. 1995;80:859–68.CrossRef
30.
Zurück zum Zitat Ikegami T, Kuraoka I, Saijo M, et al. Solution structure of the DNA- and RPA-binding domain of the human repair factor XPA. Nat Struct Biol. 1998;5:701–6.CrossRef Ikegami T, Kuraoka I, Saijo M, et al. Solution structure of the DNA- and RPA-binding domain of the human repair factor XPA. Nat Struct Biol. 1998;5:701–6.CrossRef
31.
Zurück zum Zitat Di Z, Sanyuan S, Hong L, et al. Enhanced radiosensitivity and G2/M arrest were observed in radioresistant esophageal cancer cells by knocking down RPA expression. Cell Biochem Biophys. 2014;70:887–91.CrossRef Di Z, Sanyuan S, Hong L, et al. Enhanced radiosensitivity and G2/M arrest were observed in radioresistant esophageal cancer cells by knocking down RPA expression. Cell Biochem Biophys. 2014;70:887–91.CrossRef
Metadaten
Titel
Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer
verfasst von
Shuwei Li
Kaili Xu
Dongying Gu
Lei He
Lisheng Xie
Zhengxin Chen
Zhimin Fan
Lingjun Zhu
Mulong Du
Haiyan Chu
Zhengdong Zhang
Yuan Wu
Min Ni
Meilin Wang
Publikationsdatum
28.03.2019
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 11/2019
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-019-01571-z

Weitere Artikel der Ausgabe 11/2019

Journal of Gastroenterology 11/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.